Office Of New Drugs Reorg Is Bigger Than Expected: US FDA Adds 11 Review Divisions
Executive Summary
Long-planned OND 'modernization' to better match workflow, allow more time with stakeholders includes proposed restructuring that would boost number of offices overseeing review operations (adding four for a total of nine) and drug review divisions (adding 11 for a total of 30).